Quantitative systems pharmacology

Applied BioMath, LLC to Hold Virtual Quantitative Systems Pharmacology Summit

Retrieved on: 
Tuesday, September 8, 2020
Quantitative systems pharmacology, Articles, Systems pharmacology, QSP, Pharmacology, Simulation, Nature, Branches of science

CONCORD, Mass., Sept. 8, 2020 /PRNewswire/ --Applied BioMath ( www.appliedbiomath.com ), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced that due to COVID-19 they will hold their fourth annual Quantitative Systems Pharmacology (QSP) Summit virtually on November 5, 2020 from 9 a.m. - 5 p.m.

Key Points: 
  • CONCORD, Mass., Sept. 8, 2020 /PRNewswire/ --Applied BioMath ( www.appliedbiomath.com ), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced that due to COVID-19 they will hold their fourth annual Quantitative Systems Pharmacology (QSP) Summit virtually on November 5, 2020 from 9 a.m. - 5 p.m.
  • Registrants are encouraged to submit a poster abstract for the virtual poster session.
  • Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development.
  • Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.

DILIsym Services Partners with Large Pharmaceutical Company to Begin QSP Model Development for Heart Failure

Retrieved on: 
Tuesday, February 4, 2020
Cardiology, Software, Biotechnology, Pharmaceutical, Health, Consulting, Professional services, Technology, Health sciences, Health, Pharmacology, Pharmaceutical sciences, Pharmaceutical industry, Pharmacy, Cardiac fibrosis, Medication, Quantitative systems pharmacology

As with other QSP efforts by the company, the development of this new QSP software component is being sponsored by a large pharmaceutical company partner and will be widely available via licensing and consulting for the broader pharmaceutical industry upon completion.

Key Points: 
  • As with other QSP efforts by the company, the development of this new QSP software component is being sponsored by a large pharmaceutical company partner and will be widely available via licensing and consulting for the broader pharmaceutical industry upon completion.
  • This new venture represents the companys first project focused on QSP for heart failure.
  • Simulating the mechanisms contributing to the development of cardiac fibrosis and its contributions to heart failure will enable us to support the pharmaceutical industry in the development of therapeutics to treat heart failure by predicting efficacy before real-world patients are administered potential drugs.
  • The pharmaceutical industrys use of QSP modeling approaches to improve development decision making and outcomes is increasing rapidly.

Applied BioMath, LLC to Hold Fourth Annual Quantitative Systems Pharmacology (QSP) Summit in Cambridge, MA

Retrieved on: 
Wednesday, January 8, 2020
Articles, Quantitative systems pharmacology, QSP, Systems pharmacology, Pharmacology, Poster session, Knowledge

CONCORD, Mass., Jan. 8, 2020 /PRNewswire/ --Applied BioMath ( www.appliedbiomath.com ), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their fourth annual Quantitative Systems Pharmacology (QSP) Summit will occur May 20-21, 2020 at the MIT Samberg Conference Center in Cambridge, MA.

Key Points: 
  • CONCORD, Mass., Jan. 8, 2020 /PRNewswire/ --Applied BioMath ( www.appliedbiomath.com ), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their fourth annual Quantitative Systems Pharmacology (QSP) Summit will occur May 20-21, 2020 at the MIT Samberg Conference Center in Cambridge, MA.
  • In its fourth year, the QSP Summit is a free, two-day conference featuring talks from key industry and academic researchers, a poster session with awards, and networking time with peers.
  • "Year over year we see growth at this event from the number of attendees, speakers, and poster presentations.
  • Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.

Simulations Plus to Support Development of Radiation Countermeasure via New QSP Platform (RADAsym) and Pharmacometrics Modeling

Retrieved on: 
Tuesday, October 29, 2019
Science, Software, Biotechnology, Research, Pharmaceutical, Oncology, Health, Technology, Pharmacology, Quantitative systems pharmacology, QSP, Simulation, Primate

The new QSP (Quantitative Systems Pharmacology) platform will allow for prediction of the effects of radiation on mice, non-human primates, and humans, as well as the impact of interventions on radiation syndrome.

Key Points: 
  • The new QSP (Quantitative Systems Pharmacology) platform will allow for prediction of the effects of radiation on mice, non-human primates, and humans, as well as the impact of interventions on radiation syndrome.
  • The platform will be utilized, along with the expertise of the DILIsym Services scientists, to help garner approval for the treatment under the Animal Rule .
  • Shawn OConnor , chief executive officer of Simulations Plus, added: We are pleased to have been engaged by industry to support this critical development effort.
  • Our expertise across QSP and PKPD techniques and model development positions us uniquely to satisfy the requirements of this endeavor.

DILIsym Releases NAFLDsym® Version 2A

Retrieved on: 
Thursday, June 27, 2019
Consulting, Technology, Professional services, Health, Pharmaceutical, Research, Software, Science, Pharmacology, Health sciences, Articles, Health, Quantitative systems pharmacology, Pharmaceutical industry, Simulation, Non-alcoholic fatty liver disease

DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it has released NAFLDsym Version 2A, quantitative systems pharmacology (QSP) modeling software to support the development of treatments for non-alcoholic fatty liver disease (NAFLD).

Key Points: 
  • DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it has released NAFLDsym Version 2A, quantitative systems pharmacology (QSP) modeling software to support the development of treatments for non-alcoholic fatty liver disease (NAFLD).
  • In particular, NAFLDsym v2A allows users to predict efficacy in NASH patients for combinations of treatments, which is thought to be the best path for treating this disease.
  • Thus, DILIsym and RENAsym may be applied to address drug safety across therapeutic areas, while NAFLDsym and IPFsym may be applied to support the development of efficacious drugs in these therapeutic areas.
  • DILIsym Services makes these tools available to small, mid-size and large pharmaceutical organizations and regulatory agencies through its licensing programs.

Applied BioMath, LLC Announces Speaker Lineup for Quantitative Systems Pharmacology (QSP) Summit

Retrieved on: 
Tuesday, April 16, 2019
Pharmacology, Quantitative systems pharmacology, Modeling and simulation, Simulation, QSP

CONCORD, Mass., April 16, 2019 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced the speaker lineup for the Quantitative Systems Pharmacology (QSP) Summit occurring April 25-26, 2019 at Le Meridien Boston Cambridge in Cambridge, MA.

Key Points: 
  • CONCORD, Mass., April 16, 2019 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced the speaker lineup for the Quantitative Systems Pharmacology (QSP) Summit occurring April 25-26, 2019 at Le Meridien Boston Cambridge in Cambridge, MA.
  • said John Burke, PhD, Co-Founder, President and CEO, Applied BioMath.
  • Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development.
  • Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.